Page 44 - Read Online
P. 44

Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37                                Page 329

              Ref.   Ref.   [14]  [34]  [40]     [13]       [51]   [52]    [29]   [35]        [27]



              Clinical outcomes Clinical outcomes  No association of UGT1A9   c.-275T>A variant with   gastrointestinal adverse   No association of UGT1A9   c.-275T>A and c.98T>C  variants with AR or adverse   UGT1A9 c.98TC genotype   was associated with  decreased graft function  UGT1A9 c.98TC genotype  was associated with lower  eGFR, but not with AR and   No association of UGT1A9  c.-2152C>T and c.-275T>A  variants with AR or adverse   No association of UGT1A9   c.-215







                 -                 events  -          events             DGF    events  -
              Pharmacokinetics Pharmacokinetics  No association of   UGT1A9 c.-2152C>T,   c.-440C>T, c.-275T>A   and c.98T>C variants   with MPA or MPAG   pharmacokinetics  -  No association of   UGT1A9 c.-2152C>T, c.-  275T>A and c.98T>C   pharmacokinetics  -  -  -  -  UGT1A9 c.-440CT   (or c.-331TC) and   -1818CC genotypes were   associated with higher   and lower MPAG   AUC 0-12 ,   respectively  -








             Immunosuppressive  Immunosuppressive   regimen  regimen  MMF  Cyclosporine  Tacrolimus  Sirolimus  Corticosteroids   At a point between 3-6   months  MMF  Cyclosporine Tacrolimus  Sirolimus  Up to 115 month follow-  up  MMF  Cyclosporine  Tacrolimus Corticosteroids Sixty-day variants with MPA   follow-up  MMF  Cyclosporine  Tacrolimus  mTOR inhibitor   Corticosteroids  One-year follow-up  MMF  Calcineurin inhibitors  Corticosteroids  One-year follow-up  MMF











              Population   Population   89 pediatric patients   103 adult patients   140 adult patients   284 pediatric and young   adult patients (USA)

                 185 patients  (France)  256 adult patients  (France)  (France)  218 adult patients  (France)  (Poland)  (Poland)  189 adult patients  (France)  127 adult patients   (China)






              Study design Study design  Prospective (included   multicenter Apomygre   study)  Retrospective  Prospective, multicenter  Retrospective   (Transgene study)  Retrospective (Case-  control)  Retrospective  Prospective, multicenter   (Dominos study)  Prospective  Retrospective (Case-  control) multicenter







              Allele frequency Allele frequency  c.-2152T: 6%  c.-440T: 24%  c.-275A:6%  c.98C: 3%  c.-275A: 6%  c.-2152T: 4%  c.-275A: 6%  c.98C: 2%   c.-275A: 7%  c.98C: 1%   c.-2152T: 5%  c.-275A: 4%  c.98C: 3%  c.98C: 4%  c.-2152T: 3%  c.-275A: 5%  -1818T: 13%  c.-440T: 2%  c.-331C: 2%  -118delT: 58%  I399C: 31%  -










              Variant  Variant







              Gene   Gene
   39   40   41   42   43   44   45   46   47   48   49